NeuroSense Therapeutics
NRSN
6 hedge funds and large institutions have $2.2M invested in NeuroSense Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
803% more capital invested
Capital invested by funds: $243K → $2.2M (+$1.95M)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more funds holding
Funds holding: 5 → 6 (+1)
10.19% more ownership
Funds ownership: 1.05% → 11.24% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.22M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$175K |
| 3 |
JP Morgan Chase
New York
|
+$2.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$20.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.19K |
NRSN Hedge Fund Activity: Q2 2023 in Review
6 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q2 2023, worth a combined $2.2M — up 803% from $243K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NRSN positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.22M. The largest seller was Ground Swell Capital, exiting entirely with an estimated $20.6K sold.
- 6 institutional investors held NeuroSense Therapeutics (NRSN) as of Q2 2023, up from 5 in Q1 2023.
- Funds reported $2.2M of NeuroSense Therapeutics stock for Q2 2023, up 803% quarter-over-quarter.
- 3 funds opened new NeuroSense Therapeutics positions in Q2 2023 and 2 closed out, a net change of +1 holder.
- The largest NeuroSense Therapeutics buyer in Q2 2023 was Armistice Capital, an estimated $2.22M added.
- The largest NeuroSense Therapeutics seller in Q2 2023 was Ground Swell Capital, an estimated $20.6K sold.
Based on aggregated 13F filings for Q2 2023.